# Lymphoedema Development Following a Cancer Diagnosis: An Anonymised Data Linkage Study in Wales, United Kingdom

## TL;DR

This study examines how cancer diagnoses in Wales are linked to lymphoedema development and finds that cancer type strongly influences the time to lymphoedema diagnosis.

## Contribution

The study identifies cancer type as the most significant factor affecting the time to lymphoedema development after cancer diagnosis.

## Key findings

- 7538 cases of lymphoedema were identified following cancer diagnoses in Wales.
- Breast cancer patients developed lymphoedema the fastest, likely due to surgical interventions.
- Cancer type was the strongest predictor of time to lymphoedema diagnosis.

## Abstract

This observational cohort study explored lymphoedema development following a cancer diagnosis and whether demographic factors impacted the time to lymphoedema development. We identified cases through the Secure Anonymised Information Linkage (SAIL) Databank. We used cancer diagnostic codes to identify a cohort of six broad cancer ‘types’. We independently used lymphoedema diagnostic codes to identify a cohort who developed lymphoedema. We linked these two cohorts to develop a single cohort of cases and describe the number of cases who went on to develop lymphoedema after a cancer diagnosis, and the time to lymphoedema diagnosis. We used Cox regression models to calculate hazard ratios and produced survival curves to explore whether pre‐defined factors (gender, age, deprivation, cancer type) had any impact on time to lymphoedema development. We identified 7538 cases of lymphoedema development after a cancer diagnosis, relating to 7279 people. There was considerable variation in the time to diagnosis, with a mean and standard deviation of 483.3 (701.8) days. Cancer type was the single most important factor in explaining time to lymphoedema diagnosis. Time to lymphoedema was shortest in breast cancer. A large number of breast cancer cases have undergone surgery, and this may account for the earlier development of lymphoedema. Consideration should be made of risk factors for lymphoedema development in order to allow for more targeted treatment plans that could improve health‐related quality of life for patients.